

Insurers Push Back on Medicare Coverage for Weight-Loss Drugs

Admin User · February 11, 2026

Health insurance companies are lobbying the Trump administration to reject Biden-era proposals that would expand Medicare and Medicaid prescription access to weight-loss medications such as Wegovy and Ozempic.

Health plans are urging the Trump administration to reject a proposal from the final days of the Biden presidency that would require Medicare and Medicaid to cover anti-obesity drugs, including popular GLP-1 medications like Wegovy and Ozempic, [Axios reports](#).

The insurers argue that the expanded coverage would lead to higher premiums for consumers, while proponents say it could improve health outcomes and potentially reduce long-term costs.

The decision, expected in April, will serve as a key indicator of which health care interests hold sway with President Trump, as many providers, patients and pharmaceutical companies support Medicare coverage for these weight-loss drugs.

The Biden administration's proposal aimed to reinterpret long-standing Medicare rules prohibiting coverage of most weight-loss medications, coming at a time of surging demand for GLP-1 drugs. The outcome of this policy debate could significantly impact access to these medications for millions of older Americans struggling with obesity.
